Bicara Therapeutics/$BCAX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Bicara Therapeutics

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Ticker

$BCAX
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
Boston, United States

Employees

55

ISIN

US0554771032
Website
www.bicara.com

BCAX Metrics

BasicAdvanced
$491M
-
-$3.05
-
-

Bulls say / Bears say

Bicara Therapeutics successfully closed its initial public offering in September 2024, raising $362 million, providing substantial capital to advance its pipeline of bifunctional therapies for solid tumors. (biospace.com)
Institutional investors, such as Foresite Capital Management VI LLC, have shown confidence in Bicara by purchasing significant shares, with Foresite acquiring 950,000 shares valued at approximately $16.5 million in April 2025. (marketbeat.com)
Analysts have maintained a positive outlook on Bicara, with HC Wainwright issuing a 'buy' rating and a price target of $41.00 in May 2025, indicating potential upside from the current stock price. (americanbankingnews.com)
Following the release of interim data from a clinical trial in May 2025, Bicara's stock plummeted 30% in after-hours trading, reflecting investor concerns over the trial results. (investing.com)
HC Wainwright reduced its price target for Bicara from $44.00 to $41.00 in May 2025, suggesting tempered expectations for the company's stock performance. (americanbankingnews.com)
The expiration of Bicara's lock-up period in March 2025 allowed insiders and major shareholders to sell their shares, potentially increasing stock volatility and downward pressure on the stock price. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.

BCAX News

AllArticlesVideos
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

GlobeNewsWire·1 month ago
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

GlobeNewsWire·1 month ago
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BCAX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs